# CGT4859

Source: https://onco.cc/drugs/cgt4859/  
OnCo record `cgt4859` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CGT4859 is an experimental small-molecule drug from Cogent Biosciences in phase 2 trials for biliary tract cancer, aimed at FGFR2.

## Summary

CGT4859 is a small-molecule drug developed by Cogent Biosciences. Its target is FGFR2 (the sponsor names FGFR2, FGFR3). The sponsor states: A selective FGFR2/3 inhibitor designed to target tumours with genetic alterations in these fibroblast growth factor receptors. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in biliary tract cancer. The largest, NCT06777316, plans to enrol 110 participants with primary completion expected 2027-03. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule (structure undisclosed or not yet in PubChem)
- Mechanism: A selective FGFR2/3 inhibitor designed to target tumours with genetic alterations in these fibroblast growth factor receptors.

## Sources

- ClinicalTrials.gov: trials of CGT4859: https://clinicaltrials.gov/search?intr=CGT4859

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/)
- companies: [Cogent Biosciences](https://onco.cc/companies/cogent-biosciences/)
- trials: [A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors](https://onco.cc/trials/nct06777316/)

---
JSON: https://onco.cc/api/v1/entities/cgt4859.json